Plain-English reading on the vagus nerve, its science and how to look after it
Devices & Stimulation

The Impact of Auricular Vagus Nerve Stimulation on Health and Well-being

A small unbranded grey control unit with a dark glass screen and a clip electrode on a coiled cable resting on slubby linen.


Auricular vagus nerve stimulation (aVNS, also called transcutaneous auricular VNS or taVNS) is the most studied form of non-invasive VNS — it delivers mild electrical current to the ear’s vagally innervated skin to activate brainstem circuits normally reached only by the implanted vagus nerve stimulator. This article covers the anatomy, the evidence, and the practical considerations for this approach.

The Anatomy That Makes It Work

The auricular branch of the vagus nerve (ABVN, Arnold’s nerve) is the only branch of the vagus nerve that reaches the body surface. It arises from the superior (jugular) ganglion of the vagus nerve and innervates specific regions of the external ear — primarily the cymba conchae (the upper bowl-shaped depression of the ear, above the ear canal), the tragus (the cartilage flap in front of the ear canal), and parts of the posterior ear canal and concha.

The ABVN’s central projections are what make it therapeutically interesting. Its afferent fibres project to the spinal trigeminal nucleus in the brainstem, which has dense connections to the nucleus tractus solitarius (NTS) — the primary relay nucleus of the vagus nerve. From the NTS, signals propagate to the locus coeruleus (norepinephrine system), the dorsal raphe (serotonin system), the parabrachial nucleus (interoception), and the dorsal motor nucleus of the vagus (vagal efferent output). This means that electrical stimulation of a small patch of ear skin can activate the same brainstem circuitry that the main vagal trunk uses — though with less intensity and specificity than direct vagal trunk stimulation via an implanted device.

fMRI studies have confirmed this pathway. Stimulation at the cymba conchae produces robust activation of the NTS, locus coeruleus, and limbic structures (amygdala, hippocampus, insula), while stimulation at the ear lobe (a control site with no ABVN innervation) does not. This anatomical specificity is the foundation of taVNS — where you stimulate on the ear matters.

Clinical Evidence

Epilepsy. Several pilot studies and small RCTs have shown that taVNS reduces seizure frequency in drug-resistant epilepsy, with response rates (50% or greater seizure reduction) of approximately 20-35% — lower than implanted VNS (40-50% at 2-3 years) but meaningful for patients who are not surgical candidates or prefer a non-invasive approach. The largest trial to date (Bauer et al. 2016) used a 20-week crossover design and found a significant reduction in seizure frequency with active taVNS compared to sham stimulation at the ear lobe.

Depression. Multiple RCTs have shown antidepressant effects with taVNS, including a 2016 trial by Rong et al. (Brain Stimulation) showing significant improvement in depression scores with 4 weeks of daily taVNS compared to sham. The mechanism is thought to involve NTS-locus coeruleus norepinephrine pathway activation — the same pathway that implanted VNS targets for depression. Effect sizes are modest but consistent across studies.

Atrial fibrillation. The TREAT-AF trial (Stavrakis et al. 2020, JACC) is the landmark taVNS study for cardiac applications. Low-level taVNS applied to the tragus for one hour daily over 6 months reduced AF burden by approximately 75% compared to sham stimulation. The mechanism involves vagal modulation of atrial electrophysiology — low-level vagal stimulation (below the threshold that would trigger AF) reduces atrial inflammation and stabilises the electrical substrate. This counter-intuitive finding (vagal stimulation treating a vagally triggered arrhythmia) reflects the dose-response: high-intensity vagal activation can trigger AF, while low-level sub-threshold stimulation has anti-arrhythmic properties.

Pain. taVNS has shown analgesic effects in studies of migraine, chronic pain, and acute pain. The mechanism involves NTS activation of descending pain inhibitory pathways (periaqueductal grey, rostroventral medulla) and modulation of central pain processing. Evidence is still preliminary but promising, particularly for migraine.

Inflammation. taVNS has been shown to reduce circulating levels of TNF-alpha, IL-6, and other inflammatory cytokines in several studies, consistent with activation of the cholinergic anti-inflammatory pathway (CAP). This has implications for inflammatory conditions, though most studies are small and short-term. Larger trials are underway.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

Stimulation Parameters

The clinical evidence uses a range of stimulation parameters, and optimal settings are still being established. Common parameters across the research include stimulation site (cymba conchae is best supported by fMRI evidence; tragus is also commonly used and was the site for TREAT-AF), frequency (typically 25 Hz, though some studies use 1 Hz, 10 Hz, or 30 Hz), pulse width (200-500 microseconds, with 250 microseconds most common), intensity (adjusted to just below pain threshold, typically 0.5-5 mA, producing a tingling sensation without pain), and session duration (30-60 minutes per day in most clinical trials).

Consumer devices (Pulsetto, Nurosym, Hoolest) typically default to 25 Hz, 250 microsecond pulse width, and allow user-adjustable intensity. Most recommend 30-minute sessions. These parameters are broadly consistent with the research literature, though individual device designs vary in electrode placement and current delivery characteristics.

Consumer Devices vs Clinical Devices

The distinction between consumer and clinical taVNS devices matters. Clinical taVNS devices (NEMOS by Cerbomed, Parasym by Nurosym) have been used in published clinical trials and have specific regulatory clearances in some jurisdictions. Consumer devices (Pulsetto, Hoolest, and various generic taVNS devices available online) are marketed as wellness devices rather than medical devices, which means they are not subject to the same regulatory scrutiny and their specific designs have not necessarily been validated in clinical trials.

This does not mean consumer devices are ineffective — many use similar stimulation parameters to those validated in research. But it does mean that the clinical evidence cannot be directly assumed to apply to a specific consumer device unless that device has been independently tested. When choosing a device, look for whether the specific device (not just the general concept of taVNS) has been used in published studies, whether the stimulation parameters are consistent with the evidence base, and whether the electrode placement targets the cymba conchae or tragus specifically.

For a detailed comparison of available devices and pricing, see our comprehensive review of vagus nerve stimulation devices.

Safety

taVNS has an excellent safety profile in the published literature. The most common side effects are local skin irritation at the electrode site, mild ear pain or tingling, and headache. Serious adverse events are rare. The main safety consideration is cardiac — because taVNS can modulate heart rate, people with cardiac pacemakers, implanted defibrillators, or significant cardiac arrhythmias should consult their cardiologist before using taVNS. Stimulation should be at the cymba conchae or tragus, not at the ear lobe or other non-vagal sites where the stimulation pathway and effects are less predictable. Pregnant women are typically excluded from taVNS studies as a precaution, though no specific harm has been documented.

Auricular VNS is the most accessible and well-studied form of electrical vagal stimulation — and the evidence base grows every year. My Vagus Nerve & Me covers the full spectrum of VNS approaches. Get My Vagus Nerve & Me eBook and understand your options.

This article is for general information and is not medical advice. Talk to a qualified clinician before changing anything about your health or treatment. Read our medical disclaimer. Spotted an error? Let us know.